Furui Medical (300049) 2025 Annual Report Brief Analysis: Revenue and net profit both increase year-over-year, profitability improves

According to publicly available data organized by Securities Star, recently, Furuimei Medical (300049) released its annual report for 2025. As of the end of this reporting period, the company’s total operating revenue was 1.595 billion yuan, an increase of 18.26% year-on-year, and the net profit attributable to the parent company was 154 million yuan, an increase of 36.02% year-on-year. In terms of quarterly data, total operating revenue for the fourth quarter was 494 million yuan, an increase of 33.91% year-on-year, and the net profit attributable to the parent company for the fourth quarter was 42.2029 million yuan, an increase of 274.03% year-on-year. During this reporting period, Furuimei Medical’s profitability improved, with a year-on-year increase in gross margin of 1.14% and a year-on-year increase in net profit margin of 11.56%.

This data fell short of most analysts’ expectations, as analysts had generally expected a net profit of around 219 million yuan for 2025.

The various data indicators released in this financial report performed relatively well. Among them, the gross margin was 74.97%, with a year-on-year increase of 1.14%, the net profit margin was 16.2%, with a year-on-year increase of 11.56%, and total sales, administrative, and financial expenses amounted to 692 million yuan, accounting for 43.36% of revenue, a year-on-year increase of 4.31%. The net asset value per share was 7.47 yuan, a year-on-year increase of 13.79%, the operating cash flow per share was 1.33 yuan, a year-on-year increase of 59.59%, and earnings per share were 0.58 yuan, a year-on-year increase of 34.88%.

The reasons for the significant changes in financial items in the financial statements are explained as follows:

1. The change in financial expenses was 170.56%, reason: exchange rate fluctuations.
2. The change in net cash flow from operating activities was 58.77%, reason: growth in Echosens and domestic pharmaceutical sector businesses during the period, with significant increases in procurement and labor costs, resulting in increases in both cash inflows and outflows from operating activities; however, cash inflows from transactions with external units increased significantly this period.
3. The change in net cash flow from investing activities was 30.47%, reason: the previous period involved a merger with Hangzhou Ruiying under non-same control, and there were significant outflows for investment in financial products. The purchases and recoveries of financial products remained roughly balanced this period.
4. The change in net cash flow from financing activities was -150.72%, reason: the company received distributions from an employee stock ownership plan in the previous period, resulting in significant net inflows from financing activities. This period saw a reduction in this inflow, while payments for dividends, lease payments, and listing intermediary fees increased, leading to a net outflow from financing activities.

Securities Star’s value investment circle financial report analysis tool shows:

• Business Evaluation: The company’s ROIC last year was 9.99%, which is average. The net profit margin last year was 16.2%, indicating high added value for the company’s products or services after accounting for all costs. From historical annual report data, the median ROIC over the past decade is 7.71%, with median investment returns being weak; the worst year, 2018, had an ROIC of 2.67%, indicating average investment returns. The company’s historical financial reports are relatively average.
• Business Model: The company’s performance mainly relies on marketing-driven strategies. It is essential to carefully study the underlying realities behind these driving forces.
• Business Breakdown: The company’s net operating asset return on investment for the past three years (2023/2024/2025) was 12.3%/10.9%/14.1%, with net operating profits of 177 million/196 million/258 million yuan, and net operating assets of 1.441 billion/1.794 billion/1.829 billion yuan.

The company’s working capital/revenue (i.e., the amount of funds the company needs to advance for every yuan of revenue generated during operations) for the past three years (2023/2024/2025) was 0.45/0.45/0.33, with working capital (the company’s own funds during operations) being 514 million/611 million/522 million yuan, and revenue being 1.154 billion/1.349 billion/1.595 billion yuan.

The financial report health check tool shows:

1. It is recommended to pay attention to the company’s accounts receivable situation (accounts receivable/profit has reached 288.97%).

The fund holding the most shares of Furuimei Medical is Ping An Medical Health Mixed A, currently with a scale of 1.847 billion yuan, the latest net value being 2.2082 (March 25), which is an increase of 1.42% compared to the previous trading day, with a rise of 14.35% over the past year. The current fund manager is Zhou Sicong.

Recently, well-known institutions have focused on the following questions regarding the company:

Q: Please introduce the company’s performance for the year 2025.

A: In 2025, the company’s revenue was 1.595 billion yuan, an increase of 18.26% year-on-year; the net profit attributable to the parent company was 154 million yuan, an increase of 36.02%. Among them, equipment revenue was 1.134 billion yuan, an increase of 23.48%, with equipment profit of 250 million yuan, an increase of 31.34%; drug revenue was 288 million yuan, continuing the growth trend.

The operating revenue split by quarter is as follows: Q1 was 330 million yuan; Q2 was 383 million yuan; Q3 was 388 million yuan; Q4 was 494 million yuan. The year-on-year growth rates for the quarters were 2.35%, 19.76%, 14.94%, and 33.91%.

The above content is organized by Securities Star based on publicly available information and generated by AI algorithms (Internet Information Office Backup 310104345710301240019), and does not constitute investment advice.